Ying Ni

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Aug 9, 2024 | onlinelibrary.wiley.com | Ying Ni |Zhuhai Branch |Chao Chen |Dina Zhu

Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.

Mar 1, 2024 | onlinelibrary.wiley.com | Chao Chen |Yuxi He |Ying Ni |Zhuhai Branch

1 INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and is closely related to type 2 diabetes.1 20%–30% of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH).2 In early 2020, an international panel of experts led a consensus-driven process to develop a more appropriate terminology for NAFLD.

Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more

December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.

Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more

December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.